Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate
- PMID: 24991593
- PMCID: PMC4076867
- DOI: 10.4103/2279-042X.108374
Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate
Abstract
Objective: Recently, adenosine deaminase (ADA) is introduced as helpful marker in diagnosis, prognosis, and monitoring of treatment in rheumatoid arthritis (RA). The aim of this study was to determine the efficacy of the serum ADA in diagnosis, prognosis, and monitoring of treatment with methotrexate (MTX) in RA.
Methods: This was a self-controlled clinical trial conducted in university hospitals of Isfahan, Iran. The serum level of ADA, erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) were measured for 70 patients with active RA (Disease Activity Score-28 [DAS28] > 3/2). After three months of MTX treatment and disease remission (DAS28 < 2.6) these markers were measured again. ANCOVA multiregression and paired t-test were used to compare and evaluate the mean level and correlation of ADA, ESR, IgM-RF, and DAS before and after RA remission.
Findings: The mean value for ADA activity was significantly higher than the normal one compared with other studies. Significant decreases were seen in values of ADA, ESR, RF, visual analogue scale (VAS), and DAS after remission. Also, the correlation coefficient between the values of ADA with ESR and DAS were statistically significant in baseline. Moreover, the statistically significant correlation between ADA and ESR, VAS, and DAS were seen after remission. No correlation was found in the case of the dosage of MTX with the value of ADA.
Conclusion: It was concluded that ADA may be considered useful as a marker in diagnosis, prognosis, and monitoring of treatment with Methotrexate in RA.
Keywords: Adenosine deaminase; disease activity score; methotrexate; rheumatoid arthritis.
Conflict of interest statement
Similar articles
-
Serum Adenosine Deaminase Level is High But Not Related with Disease Activity Parameters in Patients with Rheumatoid Arthritis.Open Rheumatol J. 2014 Sep 12;8:24-8. doi: 10.2174/1874312901408010024. eCollection 2014. Open Rheumatol J. 2014. PMID: 25279018 Free PMC article.
-
Adenosine Deaminase Gene Polymorphism and Baseline Serum Level of Adenosine Deaminase as a Biomarker of Response to Methotrexate in Rheumatoid Arthritis.J Clin Rheumatol. 2021 Dec 1;27(8):e609-e611. doi: 10.1097/RHU.0000000000001594. J Clin Rheumatol. 2021. PMID: 33044386
-
The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate.Intern Med. 2015;54(9):1035-41. doi: 10.2169/internalmedicine.54.4085. Epub 2015 May 1. Intern Med. 2015. PMID: 25948343
-
Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.Arthritis Care Res (Hoboken). 2017 Oct;69(10):1473-1483. doi: 10.1002/acr.23164. Epub 2017 Aug 31. Arthritis Care Res (Hoboken). 2017. PMID: 27992656 Review.
-
Mechanistic role of quercetin as inhibitor for adenosine deaminase enzyme in rheumatoid arthritis: systematic review.Cell Mol Biol Lett. 2024 Jan 16;29(1):14. doi: 10.1186/s11658-024-00531-7. Cell Mol Biol Lett. 2024. PMID: 38225555 Free PMC article.
Cited by
-
Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren's syndrome: a pilot study.Clin Oral Investig. 2019 Mar;23(3):1407-1414. doi: 10.1007/s00784-018-2570-3. Epub 2018 Jul 20. Clin Oral Investig. 2019. PMID: 30030617
-
Serum Adenosine Deaminase Level is High But Not Related with Disease Activity Parameters in Patients with Rheumatoid Arthritis.Open Rheumatol J. 2014 Sep 12;8:24-8. doi: 10.2174/1874312901408010024. eCollection 2014. Open Rheumatol J. 2014. PMID: 25279018 Free PMC article.
-
Serum Adenosine Deaminase as Inflammatory Marker in Rheumatoid Arthritis.J Clin Diagn Res. 2015 Sep;9(9):BC08-10. doi: 10.7860/JCDR/2015/14296.6483. Epub 2015 Sep 1. J Clin Diagn Res. 2015. PMID: 26500897 Free PMC article.
-
Adenosine deaminase modulates metabolic remodeling and orchestrates joint destruction in rheumatoid arthritis.Sci Rep. 2021 Jul 23;11(1):15129. doi: 10.1038/s41598-021-94607-5. Sci Rep. 2021. PMID: 34301999 Free PMC article.
-
Comparison of Adenosine Deaminase, C-reactive Protein, Uric Acid, and Rheumatoid Arthritis Levels in Patients With Rheumatoid Arthritis and Those Without Arthritis: A Review.Cureus. 2024 Apr 1;16(4):e57433. doi: 10.7759/cureus.57433. eCollection 2024 Apr. Cureus. 2024. PMID: 38699124 Free PMC article. Review.
References
-
- Samanta R, Shoukrey K, Griffiths R. Rheumatoid arthritis and anaesthesia. Anaesthesia. 2011;66:1146–59. - PubMed
-
- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19. - PubMed
-
- Nalesnik M, Nikolic JM, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis. Med Glas Ljek Komore Zenicko-Doboj Kantona. 2011;8:163–8. - PubMed
-
- Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-Miller A, Hunder GG, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum. 2004;50:43–54. - PubMed
-
- Yazici Y, Abramson SB. Rheumatoid arthritis treatment and monitoring of outcomes-where are we [corrected] in 2007? Bull NYU Hosp Jt Dis. 2007;65:300–5. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous